73 related articles for article (PubMed ID: 9131177)
1. Ex vivo inhibition of PAF-induced beta-thromboglobulin release in man by ABT-299, a potent PAF antagonist.
Albert DH; Magoc TJ; Kleinert HD; Sun E; Reyes AE; Carter GW; Summers JB
Adv Exp Med Biol; 1996; 416():381-7. PubMed ID: 9131177
[No Abstract] [Full Text] [Related]
2. Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist.
Albert DH; Magoc TJ; Menacherry SD; Morgan DW; Sun E; Reyes AE; Kleinert HD; Carter GW; Summers JB
Inflamm Res; 1997 Jul; 46(7):272-7. PubMed ID: 9266276
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of endotoxin-induced pathophysiology by a new potent PAF receptor antagonist.
Kruse-Elliott KT; Albert DH; Summers JB; Carter GW; Zimmerman JJ; Grossman JE
Shock; 1996 Apr; 5(4):265-73. PubMed ID: 8721386
[TBL] [Abstract][Full Text] [Related]
4. Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist.
Albert DH; Conway RG; Magoc TJ; Tapang P; Rhein DA; Luo G; Holms JH; Davidsen SK; Summers JB; Carter GW
J Pharmacol Exp Ther; 1996 Jun; 277(3):1595-606. PubMed ID: 8667228
[TBL] [Abstract][Full Text] [Related]
5. ABT-299, a potent antagonist of platelet activating factor.
Summers JB; Albert DH; Davidsen SK; Conway RG; Holms JH; Magoc TJ; Luo G; Tapang P; Rhein DA; Carter GW
Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():475-7. PubMed ID: 7732895
[No Abstract] [Full Text] [Related]
6. Effect of platelet-activating factor-receptor antagonism on endotoxin-induced lung dysfunction in sheep.
Snapper JR; Lu W; Lefferts PL; Thabes JS
J Appl Physiol (1985); 1998 May; 84(5):1610-4. PubMed ID: 9572806
[TBL] [Abstract][Full Text] [Related]
7. ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats.
Albert DH; Luo G; Magoc TJ; Tapang P; Holms JH; Davidsen SK; Summers JB; Carter GW
Shock; 1996 Aug; 6(2):112-7. PubMed ID: 8856845
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
9. PAF-induced platelet aggregation ex vivo as a method for monitoring pharmacological activity in healthy volunteers.
Adamus WS; Heuer H; Meade CJ
Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):415-20. PubMed ID: 2747341
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ex-vivo PAF-induced platelet aggregation by the PAF-antagonist RP 48740: relationship to plasma concentrations in healthy volunteers.
Pinquier JL; Sedivy P; Bruno R; Bompart F; Gregoire J; Strauch G; Gaillot J; Clucas A
Eur J Clin Pharmacol; 1991; 41(2):141-5. PubMed ID: 1743246
[TBL] [Abstract][Full Text] [Related]
11. 4-substituted 2-alkoxytetrahydrofurans as potent and long-lasting PAF antagonists.
Carceller E; Merlos M; Giral M; Bartrolí J; García-Rafanell J; Forn J
J Med Chem; 1992 Feb; 35(4):676-83. PubMed ID: 1542094
[TBL] [Abstract][Full Text] [Related]
12. N-(acyloxyalkyl)pyridinium salts as soluble prodrugs of a potent platelet activating factor antagonist.
Davidsen SK; Summers JB; Albert DH; Holms JH; Heyman HR; Magoc TJ; Conway RG; Rhein DA; Carter GW
J Med Chem; 1994 Dec; 37(26):4423-9. PubMed ID: 7799395
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
Herbert JM; Laplace MC; Maffrand JP
J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profile of TCV-309--a potent PAF antagonist.
Terashita Z; Takatani M; Nishikawa K
J Lipid Mediat; 1992; 5(2):183-5. PubMed ID: 1445598
[TBL] [Abstract][Full Text] [Related]
15. Involvement of nitric oxide and eicosanoids in platelet-activating factor-induced haemodynamic and haematological effects in dogs.
Noguchi K; Matsuzaki T; Shiroma N; Ojiri Y; Sakanashi M
Br J Pharmacol; 1996 Jun; 118(4):941-50. PubMed ID: 8799566
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of andrographolide from Andrographis paniculata on PAF-induced platelet aggregation.
Amroyan E; Gabrielian E; Panossian A; Wikman G; Wagner H
Phytomedicine; 1999 Mar; 6(1):27-31. PubMed ID: 10228608
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of adrenaline-induced human platelet aggregation by the structurally related Paf antagonist Ro 19-3704.
Schattner M; Parini A; Fouque F; Vargaftig BB; Touqui L
Br J Pharmacol; 1989 Apr; 96(4):759-66. PubMed ID: 2787179
[TBL] [Abstract][Full Text] [Related]
19. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
Terashita Z; Imura Y; Takatani M; Tsushima S; Nishikawa K
J Pharmacol Exp Ther; 1987 Jul; 242(1):263-8. PubMed ID: 3612533
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
